Immatics (NASDAQ:IMTXW) Short Interest Update

Immatics (NASDAQ:IMTXW) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 15,100 shares, a decline of 8.5% from the December 15th total of 16,500 shares. Based on an average trading volume of 34,400 shares, the days-to-cover ratio is currently 0.4 days.

Immatics Stock Performance

NASDAQ IMTXW opened at $0.05 on Friday. The firm’s fifty day moving average is $0.33 and its two-hundred day moving average is $1.62. Immatics has a one year low of $0.02 and a one year high of $4.14.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.